Literature DB >> 22527232

Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.

Carlo Pozzilli1, Bernd Schweikert, Ugo Ecari, Wolfgang Oentrich, Jörg-Peter Bugge.   

Abstract

Enhancing quality of life (QoL) is an important objective of disease-modifying therapies in multiple sclerosis (MS). Strategies to substantiate the effect on QoL and depression have been suggested, including injection devices and nursing support. This study assesses QoL and depression in MS patients treated with interferon beta-1b (IFNB-1b) and evaluates the impact of different elements of a patient support programme and of coping strategies on QoL and depression. A prospective, observational, 2-year cohort study was conducted. MS patients were eligible if they had previously switched to IFNB-1b. Data were collected every 6 months. For the measurement of QoL the Functional Assessment of MS (FAMS) was used. Depression symptoms were assessed using the Center for Epidemiologic Studies Depression Scale (CES-D); coping strategies were assessed using the 66-item version of Ways of Coping Questionnaire. A total of 1,077 patients were recruited into the study. Seven hundred (65 %) patients completed the study. Within the subgroup completing questionnaires on QoL (N = 472) and depression (N = 363), QoL increased (110.4 vs. 115.8, p < 0.001), and the proportion of depressed patients decreased from 53.7 to 43.3 % (p < 0.001). Modelling QoL and depressions, the use of the autoinjector Betaject(®) over time showed a positive association with QoL (p = 0.049). The support from a nurse was positively associated with lower depressive symptoms (p = 0.039). The coping strategies 'planful problem-solving' and 'positive reappraisal' were associated with higher QoL and lower depressive symptoms. Patients on IFNB-1b treatment who were included in the patient support programme and completed the study showed an improvement in QoL. Moreover, compared to baseline the proportion of depressive patients decreased. Coping strategies as well as supportive elements such as autoinjectors and nurses had a significant impact on QoL and depression. However, the study had the general limitations of a non-controlled design.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527232     DOI: 10.1007/s00415-012-6492-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  39 in total

1.  Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study.

Authors:  Carlo Pozzilli; Bernd Schweikert; Ugo Ecari; Wolfgang Oentrich
Journal:  J Neurol Sci       Date:  2011-06-01       Impact factor: 3.181

2.  Evaluation of a MS specialist nurse programme.

Authors:  Angus Forbes; Alison While; Lucia Mathes; Peter Griffiths
Journal:  Int J Nurs Stud       Date:  2006-01-18       Impact factor: 5.837

3.  The performance of the Center for Epidemiologic Study Depression Scale (CES-D) in an Arab female community.

Authors:  R Ghubash; T K Daradkeh; K S Al Naseri; N B Al Bloushi; A M Al Daheri
Journal:  Int J Soc Psychiatry       Date:  2000

4.  Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b.

Authors:  C Borràs; J Río; J Porcel; M Barrios; M Tintoré; X Montalban
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

5.  Validation of the functional assessment of multiple sclerosis quality of life instrument.

Authors:  D F Cella; K Dineen; B Arnason; A Reder; K A Webster; G karabatsos; C Chang; S Lloyd; J Steward; D Stefoski
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

6.  A health-related quality of life measure for multiple sclerosis.

Authors:  B G Vickrey; R D Hays; R Harooni; L W Myers; G W Ellison
Journal:  Qual Life Res       Date:  1995-06       Impact factor: 4.147

7.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

8.  Health-related quality of life in multiple sclerosis: effects of natalizumab.

Authors:  Richard A Rudick; Deborah Miller; Steve Hass; Michael Hutchinson; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Ludwig Kappos; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
Journal:  Ann Neurol       Date:  2007-10       Impact factor: 10.422

9.  Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.

Authors:  P D Molyneux; G J Barker; F Barkhof; K Beckmann; F Dahlke; M Filippi; M Ghazi; D Hahn; D MacManus; C Polman; C Pozzilli; L Kappos; A J Thompson; K Wagner; T Yousry; D H Miller
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

10.  Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life.

Authors:  Deborah Miller; Richard A Rudick; Michael Hutchinson
Journal:  Neurology       Date:  2010-04-27       Impact factor: 9.910

View more
  12 in total

1.  Health-related quality of life and depressive symptoms in Friedreich ataxia.

Authors:  Javier Pérez-Flores; Atteneri Hernández-Torres; Fernando Montón; Antonieta Nieto
Journal:  Qual Life Res       Date:  2019-09-28       Impact factor: 4.147

2.  Coping strategies have a strong impact on quality of life, depression, and embitterment in patients with Cushing's disease.

Authors:  Sonja Siegel; Monika Milian; Bernadette Kleist; Tsambika Psaras; Maria Tsiogka; Dagmar Führer; Maria Koltowska-Häggström; Jürgen Honegger; Oliver Müller; Ulrich Sure; Christa Menzel; Michael Buchfelder; Ilonka Kreitschmann-Andermahr
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

3.  Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial.

Authors:  Laura De Giglio; Fabiana Marinelli; Valeria T Barletta; Veronica A Pagano; Floriana De Angelis; Fulvia Fanelli; Nikolaos Petsas; Patrizia Pantano; Valentina Tomassini; Carlo Pozzilli
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

4.  Importance of Coping in the Relationship Between Executive Function and Quality of Life in People with Multiple Sclerosis.

Authors:  Lisa B Grech; Litza A Kiropoulos; Katherine M Kirby; Ernest Butler; Mark Paine; Robert Hester
Journal:  Int J MS Care       Date:  2019 Sep-Oct

5.  Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b.

Authors:  Ivonne Weller; Anna Saake; Thomas Schreiner; Julika Vogelreuter; Nicolas Petroff
Journal:  Patient Prefer Adherence       Date:  2015-07-07       Impact factor: 2.711

6.  Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.

Authors:  Ingo Kleiter; Michael Lang; Judith Jeske; Christiane Norenberg; Barbara Stollfuß; Markus Schürks
Journal:  BMC Neurol       Date:  2017-09-06       Impact factor: 2.474

7.  Target Coping Strategies for Interventions Aimed at Maximizing Psychosocial Adjustment in People with Multiple Sclerosis.

Authors:  Lisa B Grech; Litza A Kiropoulos; Katherine M Kirby; Ernest Butler; Mark Paine; Robert Hester
Journal:  Int J MS Care       Date:  2018 May-Jun

8.  A Fresh Look at the Potential Mechanisms of Progressive Muscle Relaxation Therapy on Depression in Female Patients With Multiple Sclerosis.

Authors:  Seyyedeh Zahra Safi
Journal:  Iran J Psychiatry Behav Sci       Date:  2015-03-21

9.  Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).

Authors:  Tjalf Ziemssen; Lauren Sylvester; Mark Rametta; Amy Perrin Ross
Journal:  Neurol Ther       Date:  2015-10-27

Review 10.  Managing treatment fatigue in patients with multiple sclerosis on long-term therapy: the role of multiple sclerosis nurses.

Authors:  Ann Crawford; Sally Jewell; Holly Mara; Laura McCatty; Regina Pelfrey
Journal:  Patient Prefer Adherence       Date:  2014-08-19       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.